Canaccord Genuity set a $85.00 price objective on Radius Health, Inc. (NASDAQ:RDUS) in a report published on Monday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.
“Date and time of first dissemination: July 31, 2017, 12:01 ET Date and time of production: July 31, 2017, 12:01 ET Target Price / Valuation Methodology: Radius Health - RDUS Our $85 price target is based on a probability adjusted EV/S methodology.”,” Canaccord Genuity’s analyst commented.
Several other analysts have also weighed in on RDUS. Cantor Fitzgerald set a $58.00 price objective on Radius Health and gave the company a buy rating in a report on Sunday, July 23rd. BidaskClub downgraded Radius Health from a buy rating to a hold rating in a report on Tuesday, July 11th. Jefferies Group LLC set a $34.00 target price on Radius Health and gave the company a hold rating in a report on Monday, June 5th. Cowen and Company downgraded Radius Health from an outperform rating to a market perform rating in a report on Tuesday, May 2nd. Finally, HC Wainwright reaffirmed a buy rating and set a $63.00 target price on shares of Radius Health in a report on Friday, May 5th. Two analysts have rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus price target of $55.67.
Shares of Radius Health (RDUS) traded up 0.57% on Monday, hitting $44.28. The stock had a trading volume of 472,132 shares. The firm’s market cap is $1.92 billion. The company’s 50-day moving average price is $44.09 and its 200 day moving average price is $40.60. Radius Health has a 12-month low of $31.58 and a 12-month high of $59.88.
Radius Health (NASDAQ:RDUS) last announced its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.18) by $0.14. During the same quarter last year, the business posted ($0.94) earnings per share. On average, equities research analysts forecast that Radius Health will post ($4.81) earnings per share for the current fiscal year.
In other Radius Health news, major shareholder Growth N. V. Biotech purchased 43,400 shares of the company’s stock in a transaction that occurred on Monday, May 8th. The shares were purchased at an average cost of $35.57 per share, with a total value of $1,543,738.00. Following the completion of the transaction, the insider now owns 4,785,999 shares of the company’s stock, valued at $170,237,984.43. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Growth N. V. Biotech purchased 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 9th. The shares were acquired at an average cost of $35.93 per share, for a total transaction of $1,796,500.00. Following the completion of the transaction, the insider now directly owns 4,858,799 shares of the company’s stock, valued at approximately $174,576,648.07. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 273,400 shares of company stock valued at $9,559,538. 15.00% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of RDUS. Creative Planning raised its position in Radius Health by 11.5% in the first quarter. Creative Planning now owns 16,685 shares of the biopharmaceutical company’s stock valued at $645,000 after buying an additional 1,720 shares during the last quarter. DUPONT CAPITAL MANAGEMENT Corp acquired a new position in Radius Health during the first quarter valued at $304,000. OppenheimerFunds Inc. raised its position in Radius Health by 0.3% in the first quarter. OppenheimerFunds Inc. now owns 301,631 shares of the biopharmaceutical company’s stock valued at $11,658,000 after buying an additional 831 shares during the last quarter. Russell Investments Group Ltd. acquired a new position in Radius Health during the fourth quarter valued at $197,000. Finally, Trexquant Investment LP acquired a new position in Radius Health during the first quarter valued at $241,000. 99.50% of the stock is currently owned by hedge funds and other institutional investors.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
